Revenue segments as reported by the company.

Consumer Health

Pharmaceutical

Medical Devices

Innovative Medicine

MedTech

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, marketing and administrative expenses

Research and development expense

In-process research and development

Interest expense

Other expense

Restructuring

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Johnson & Johnson

Band-Aid is a brand name of American pharmaceutical and medical devices giant Johnson & Johnson's line of adhesive bandages.

Band-Aid

Johnson's Baby is an American brand of baby cosmetics and skin care products owned by Johnson & Johnson. The brand dates back to 1893 when Johnson's Baby Powder was introduced. Product line consists of baby powder, shampoos, body lotions, massage oil, shower gels and baby wipes. The brand has reputation for making baby products that are "exceptionally pure and safe" since at least the 1980s.

Johnson's Baby

Aveeno is a brand of skin care and hair care products in the United States owned by American consumer goods and pharmaceutical company Johnson & Johnson. Aveeno was founded in 1945, and its first product was their Soothing Bath Treatment. The active ingredient in all Aveeno products are colloidal oats and/or oat extracts - Avenanthramides, which have been branded as "active naturals". Aveeno offers products to treat skin conditions such as eczema, psoriasis, urushiol-induced contact dermatitis, pruritus ani, chickenpox, hives, and sunburn.

Aveeno

Neutrogena is an American brand of skin care, hair care and cosmetics, that is headquartered in Los Angeles, California. According to product advertising at their website, Neutrogena products are distributed in more than 70 countries. Neutrogena was founded in 1930 by Emanuel Stolaroff, and was originally a cosmetics company named Natone. It is now part of the US-based Johnson & Johnson conglomerate, which bought the independent company in 1994.

Neutrogena

Clean & Clear is a line of dermatology products owned by Johnson & Johnson.

Clean & Clear

Listerine is a brand of antiseptic mouthwash product. It is promoted with the slogan "Kills germs that cause bad breath". Named after Joseph Lister, a pioneer of antiseptic surgery, Listerine was developed in 1879 by Joseph Lawrence, a chemist in St. Louis, Missouri.

Listerine

Acuvue (from "Accurate view") is a brand of disposable contact lenses made by Jacksonville-based Vistakon, a subsidiary of Johnson & Johnson (J&J).

Acuvue

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Johnson & Johnson reports solid Q4 earnings, eyes $60B Pharma revenue

Johnson & Johnson's Q4 2022 showed steady operational growth and strong financial performance. The company aims for continued growth in Pharmaceuticals, focusing on key products and pipeline advancements. Challenges include managing costs, addressing sales declines, and navigating market uncertainties.

Johnson & Johnson reports resilient Q1 performance amidst challenges

Johnson & Johnson's Q1 2023 performance reflects resilience and growth across key segments despite short-term challenges.
The company's strategic focus on innovation, resource management, and portfolio diversification positions it for future success.
While facing legal and financial headwinds, Johnson & Johnson remains optimistic about its outlook for 2023 and beyond.
Increased guidance, product developments, and commitment to safety and innovation underscore the company's long-term growth potential.

Johnson & Johnson reports strong Q2 earnings and strategic growth plans

Johnson & Johnson showcased robust financial results in Q2, raising full-year guidance and highlighting growth in MedTech and Pharmaceuticals. Despite challenges from pricing pressures and litigation, the company remains focused on strategic opportunities and maintaining a strong market position. With a clear focus on innovation and growth, Johnson & Johnson is poised for continued success in the healthcare sector.

Johnson & Johnson posts strong Q3 results amidst growth strategies

Johnson & Johnson (JNJ) delivered robust Q3 results, showcasing growth in sales, earnings, and operational efficiency across key segments, positioning the company for future success.
While facing challenges from geopolitical factors, legal issues, and upcoming competition, JNJ's strategic strengths in acquisitions, innovation, and market presence offer avenues for sustained growth.
With a focus on key brands, pipeline advancements, and MedTech innovations, JNJ remains poised to meet revenue targets, navigate challenges, and capitalize on market opportunities in the coming years.

Johnson & Johnson reports robust 2023 performance and strategic growth outlook

Johnson & Johnson's strong 2023 performance in Innovative Medicine and MedTech drove operational sales growth. Despite inflationary pressures impacting margins, JNJ remains focused on enhancing shareholder returns and pursuing strategic M&A deals. Opportunities for growth in 2024 include new product launches and advancements in key focus areas.

Johnson & Johnson posts strong Q1 earnings, eyes growth opportunities

Johnson & Johnson's Q1 2024 earnings reflect solid performance across key segments, with a focus on innovation and strategic growth initiatives.
Despite challenges in certain segments, the company's proactive approach to restructuring and market dynamics positions it for future success.
Opportunities in Vision Care, Pulmonary Hypertension, and Orthopaedics underscore potential for sustained growth and market leadership.
Overall, Johnson & Johnson's diversified product portfolio and financial outlook support confidence in achieving growth targets for 2024.

Johnson & Johnson posts strong Q2 results, eyes growth opportunities

Johnson & Johnson delivered a robust performance in Q2 2024, driven by strong sales growth in both Innovative Medicine and MedTech segments, supported by strategic initiatives.
While facing challenges in certain markets and the need for continued innovation, the company's outlook remains positive with a solid guidance for the full year 2024.
By capitalizing on opportunities in key products and markets, Johnson & Johnson is well-positioned to navigate challenges and drive sustainable growth in the healthcare sector.

Johnson & Johnson reports robust Q3 earnings amidst legal challenges

Johnson & Johnson's Q3 2024 earnings call showcased strong financial performance, driven by growth in key segments and successful product launches. Despite facing challenges with talc litigation, the company remains focused on innovation, capital allocation, and resolving legal issues.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Fortis

Target

A dividend aristocrat is an S&P 500 stock that has raised its dividend annually for at least 25 years. These are typically the kinds of blue-chip stocks many fund managers with a dividend mandate tend to focus on, and for good reason. Finding companies that have been able to grow their earnings so reliably they can raise their distributions to shareholders over very long periods of time is certainly important.

3 Dividend Kings to Buy for Big Long-Term Total Returns

Third-quarter results exceeded estimates, but the company also lowered overall earnings expectations for 2024.

Johnson & Johnson Beats Wall Street Estimates. Is It Time to Buy, Sell, or Hold?

BRIDGEPORT, Conn.--(BUSINESS WIRE)--A Bridgeport jury has awarded Evan Plotkin and his wife Martha Barry-Plotkin $15 million in a verdict against pharmaceutical giant Johnson & Johnson (NYSE:JNJ) and several subsidiaries for damage linked to asbestos in the company's talc-based Baby Powder. “This trial demonstrated once again that J&J knew its products would cause harm, but they chose to do the wrong thing time and time again,” said Mr. Plotkin's attorney, Ben Braly of Dean Omar Branham.

Connecticut Jury Delivers $15 Million Asbestos Verdict Against Johnson & Johnson

Johnson & Johnson must pay $15 million to a Connecticut man who alleges that he developed mesothelioma, a rare form of cancer, as a result of using the company's talc powder for decades, a jury found on Tuesday.

J&J must pay $15 mln to Connecticut man who says its talc gave him cancer, jury finds

Johnson & Johnson reported a strong increase in sales, but earnings fell due to one-time charges.

Johnson & Johnson Q3 EPS Dips on Charges

Johnson & Johnson (JNJ) stock is experiencing a positive trading day following the announcement of its Q3 results for 2024. The earnings per share (EPS) surpassed estimates, although improved business performance was overshadowed by the recent acquisition of V-Wave, a cardiac device company.

Are JNJ's mergers and acquisitions weighing down company's performance?

U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite falling around 150 points on Tuesday.

Nasdaq Down 150 Points; Johnson & Johnson Reports Better-Than-Expected Q3 Results

Johnson & Johnson (NYSE:JNJ) shares moved higher after the pharmaceutical giant posted better-than-expected results for the third quarter. Earnings per share (EPS) of $2.42 were down from $2.66 in the year-ago quarter but topped estimates of $2.22.

J&J beats Q3 earnings estimates, raises full-year sales guidance

Johnson & Johnson (NYSE:JNJ ) Q3 2024 Earnings Conference Call October 15, 2024 8:30 AM ET Company Participants Jessica Moore - Vice President, Investor Relations Joaquin Duato - Chairman & Chief Executive Officer Joe Wolk - Executive Vice President, Chief Financial Officer Erik Haas - Head, Worldwide Litigation Tim Schmid - Executive Vice President, Worldwide Chairman, MedTech Jennifer Taubert - Executive Vice President, Worldwide Chairman, Innovative Medicine John Reed - Executive Vice President, Innovative Medicine, R&D Conference Call Participants Chris Schott - JPMorgan Larry Biegelsen - Wells Fargo Louise Chen - Cantor Fitzgerald Terence Flynn - Morgan Stanley Danielle Antalffy - UBS Shagun Singh - RBC Capital Markets Vamil Divan - Guggenheim Securities Jayson Bedford - Raymond James Operator Good morning, and welcome to Johnson & Johnson's Third Quarter 2024 Earnings Conference Call. All participants will be in a listen-only mode until the question-and-answer session of the conference.

Johnson & Johnson (JNJ) Q3 2024 Earnings Call Transcript

JNJ beats estimates for third-quarter earnings and sales. It lowers earnings expectations for 2024 but raises the sales guidance range.

J&J Beats on Q3 Earnings, Raises Sales View but Cuts EPS Guidance

Shares of Johnson & Johnson (NYSE:JNJ) are up 2.4% to trade at $165.43 this morning, after the company posted a third-quarter beat and hiked its full-year revenue guidance.

Blue Chip Faces Off With Resistance After Earnings

Johnson & Johnson (JNJ) posted better sales than expected for the third quarter, but profit fell short of analysts' estimates as the company reported billions in one-time expenses like legal costs and acquisitions.

Johnson & Johnson Posts Weaker-Than-Expected Profit on Billions in Legal Costs

While the top- and bottom-line numbers for Johnson & Johnson (JNJ) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Johnson & Johnson (JNJ) Reports Q3 Earnings: What Key Metrics Have to Say

I reiterate a “Buy” rating for Johnson & Johnson, driven by their robust cardiovascular device portfolio and recent acquisitions, with a fair value of $195 per share. The acquisition of V-Wave enhances Johnson & Johnson's MedTech business, opening new opportunities in the high-growth heart failure device market. Johnson & Johnson's Q3 results exceeded expectations, with 26.5% year-over-year growth in the cardiovascular market and a 5.4% adjusted operational revenue growth.

Johnson & Johnson Q3: Strengthening Cardiovascular Device Portfolio

Johnson & Johnson (JNJ) came out with quarterly earnings of $2.42 per share, beating the Zacks Consensus Estimate of $2.22 per share. This compares to earnings of $2.66 per share a year ago.

Johnson & Johnson (JNJ) Tops Q3 Earnings and Revenue Estimates

Johnson & Johnson beat Q3 views but slightly cut full-year EPS targets. J&J stock fell early Tuesday.

Johnson & Johnson Earnings Top; Dow Giant Falls Amid Lowered Outlook

First FcRn blocker to demonstrate sustained disease control over 24 weeks in antibody positive adolescents aged 12 – 17 years, broadening the population in which nipocalimab has been studied  SAVANNAH, Ga. , Oct. 15, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced positive results from the Phase 2/3 Vibrance-MG study of nipocalimab in anti-AChRa positive adolescents (aged 12 – 17 years) living with generalized myasthenia gravis (gMG).

Nipocalimab demonstrates sustained disease control in adolescents living with generalized myasthenia gravis in Phase 2/3 study

Johnson & Johnson shares rose 0.7% in premarket trades Tuesday after the drugmaker reported better-than-expected third-quarter sales and raised full-year revenue guidance.

Johnson & Johnson stock rises on Q3 sales beat and guidance raise

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has declared a cash dividend for the fourth quarter of 2024 of $1.24 per share on the company's common stock. The dividend is payable on December 10, 2024 to shareholders of record at the close of business on November 26, 2024. The ex-dividend date is November 26, 2024. About Johnson & Johnson At Johnson & Johnson, we believe health is everything. Our strength in healthcar.

Johnson & Johnson Announces Quarterly Dividend for Fourth Quarter 2024

Johnson & Johnson raised its 2024 profit and sales forecasts on Tuesday after reporting strong sales of oncology drugs and quarterly results that beat Wall Street expectations.

J&J lifts profit and sales forecasts, beats Wall Street expectations

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) today announced results for third-quarter 2024. “Johnson & Johnson's strong results in the third quarter reflect the unique breadth of our business and commitment to delivering the next wave of healthcare innovation,” said Joaquin Duato, Chairman and Chief Executive Officer. “During the quarter, we advanced our pipeline with regulatory approvals for TREMFYA and RYBREVANT, submitted an IDE for our general surgery robotic.

Johnson & Johnson Reports Q3 2024 Results

Johnson & Johnson JNJ will release earnings results for its third quarter before the opening bell on Tuesday, Oct. 15.

Johnson & Johnson Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Johnson & Johnson JNJ is set to announce its third quarter earnings on Oct. 15 before the market opens. Wall Street is expecting the pharmaceutical and healthcare giant to post earnings per share (EPS) of $2.21 and revenue of $22.16 billion.

Johnson & Johnson Preps For Q3 Earnings As MedTech Expands, But Stock Sends Mixed Signals

AbbVie

Merck

The size of the pharmaceutical industry in the U.S. in 2023 was estimated to be nearly $575 billion, with an anticipated compound growth rate of about 5.5% through 2030. This key component of the healthcare sector includes both small biotech firms working to develop specialized treatments and much larger, established companies engaging in a wide array of health-related operations.

Best Pharma Stocks for Long-Term Investors: Growth and Dividends

Johnson & Johnson's Q3 2024 earnings report will highlight its MedTech division, driven by strategic acquisitions and R&D investments in cardiovascular and orthopedic solutions. Despite lagging behind the S&P in price growth, JNJ offers a solid income investment with a 3.09% dividend yield and steady financials. Risks include short-term costs from acquisitions, supply chain issues in the Vision division, and external pressures like currency fluctuations and competition.

News for Johnson & Johnson Stock (JNJ)